Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis

NCT00453401 is registered in ClinicalTrials.gov with NanoBio Corporation as lead sponsor.

NCT NCT00453401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00453401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety, Pharmacokinetics, and Efficacy of NB-001 (0.1%, 0.3%, 0.5%) in Subjects With Recurrent Herpes Labialis
Lead sponsor
NanoBio Corporation
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
December 31, 2007
Enrollment
1,000 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

herpes labialis